drugset / Trial / NCT01645735
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether ceftaroline is effective and safe for the treatment of patients with Community-acquired Bacterial Pneumonia (CABP) at risk for infection due to Methicillin-resistant Staphylococcus aureus (MRSA).
Timeline
- Start
- 2012-10
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceftaroline fosamil | Other / unclassified | 600 mg | Intravenous |
| Comparator | Ceftriaxone | Other / unclassified | 2 g | Intravenous |
| Comparator | Vancomycin | Other / unclassified | 15 mg/kg | Intravenous |